Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa Study of ESN364 in Women With Polycystic Ovarian Syndrome
2014-004409-34Phase 2Completed
- Sponsor
- Ogeda
- Start
- Dec 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of fezolinetant in polycystic ovary syndrome (PCOS) (3 arms), sponsored by Ogeda. Primary endpoint: Change in total testosterone at Week 12. Started Dec 2014; status: completed.
02
Drugs
fezolinetant
03
Conditions
polycystic ovary syndrome (PCOS)
Beyond the preview
Go deeper on 2014-004409-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-004409-34.